iShares US Pharmaceuticals ETF
108 hedge funds and large institutions have $285M invested in iShares US Pharmaceuticals ETF in 2017 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 24 increasing their positions, 37 reducing their positions, and 10 closing their positions.
119% more call options, than puts
Call options by funds: $540K | Put options by funds: $247K
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
7% more funds holding
Funds holding: 101 → 108 (+7)
2.35% less ownership
Funds ownership: 148.47% → 146.12% (-2.3%)
10% less capital invested
Capital invested by funds: $317M → $285M (-$32M)
35% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 37
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mawer Investment Management
Calgary,
Alberta, Canada
|
+$8.19M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$5.19M |
| 3 |
LPL Financial
San Diego,
California
|
+$659K |
| 4 |
TC
Telemus Capital
Southfield,
Michigan
|
+$499K |
| 5 |
TFF
The Family Firm
Bethesda,
Maryland
|
+$271K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$7.53M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$6.48M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$6.07M |
| 4 |
RTS
Round Table Services
Westfield,
New Jersey
|
-$5.45M |
| 5 |
Morgan Stanley
New York
|
-$3.24M |
IHE Hedge Fund Activity: Q4 2017 in Review
108 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q4 2017, worth a combined $285M — down 10% from $317M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new IHE positions and 10 closed out — a net gain of 8 holders — while 24 added to existing stakes and 37 trimmed.
The largest buyer was Mawer Investment Management, opening a new position worth an estimated $8.19M. The largest seller was Two Sigma Securities, cutting an estimated $7.53M.
- 108 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q4 2017, up from 101 in Q3 2017.
- Funds reported $285M of iShares US Pharmaceuticals ETF stock for Q4 2017, down 10% quarter-over-quarter.
- 18 funds opened new iShares US Pharmaceuticals ETF positions in Q4 2017 and 10 closed out, a net change of +8 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q4 2017 was Mawer Investment Management, an estimated $8.19M added.
- The largest iShares US Pharmaceuticals ETF seller in Q4 2017 was Two Sigma Securities, an estimated $7.53M sold.
Based on aggregated 13F filings for Q4 2017.